Soleno Therapeutics Inc SLNO
We take great care to ensure that the data presented and summarized in this overview for SOLENO THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SLNO
Top Purchases
Top Sells
About SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Insider Transactions at SLNO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 21
2025
|
Patricia C Hirano |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+5.39%
|
-
|
|
Jan 21
2025
|
Michael F. Huang Sr. VP of Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+13.39%
|
-
|
|
Jan 21
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,500
+10.34%
|
-
|
|
Jan 21
2025
|
Meredith Manning Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,600
+20.24%
|
-
|
|
Jan 21
2025
|
Kristen Yen |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+7.16%
|
-
|
|
Jan 21
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
53,900
+6.69%
|
-
|
|
Jan 03
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,154
-1.43%
|
$467,084
$46.18 P/Share
|
|
Jan 03
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
1,459
-1.36%
|
$67,114
$46.18 P/Share
|
|
Jan 03
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,791
-3.29%
|
$174,386
$46.18 P/Share
|
|
Jan 03
2025
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
2,340
-2.96%
|
$107,640
$46.18 P/Share
|
|
Jan 02
2025
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,937
-0.76%
|
$492,165
$45.64 P/Share
|
|
Jan 02
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
1,571
-0.72%
|
$70,695
$45.64 P/Share
|
|
Jan 02
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,083
-1.72%
|
$183,735
$45.64 P/Share
|
|
Jan 02
2025
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
2,520
-1.55%
|
$113,400
$45.64 P/Share
|
|
Oct 01
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,077
-3.19%
|
$395,773
$49.8 P/Share
|
|
Oct 01
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
3,108
-1.84%
|
$152,292
$49.8 P/Share
|
|
Oct 01
2024
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
3,108
-1.39%
|
$152,292
$49.8 P/Share
|
|
Oct 01
2024
|
Bhatnagar Anish CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
21,633
-1.46%
|
$1,060,017
$49.8 P/Share
|
|
Aug 29
2024
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,870
-2.58%
|
$322,890
$47.5 P/Share
|
|
Aug 29
2024
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
5,435
-3.05%
|
$255,445
$47.5 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.34M shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 62K shares |
| Open market or private sale | 2.58M shares |
|---|